158 related articles for article (PubMed ID: 34151698)
1. COVID-19 vaccination in patients on rituximab: a survey of lymphoma physicians at NCI designated cancer centers.
Messmer M; Wagner-Johnston N
Leuk Lymphoma; 2021 Dec; 62(12):3019-3022. PubMed ID: 34151698
[No Abstract] [Full Text] [Related]
2. Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli
Chung SH; Wener M; Bays AM; Rahbar H; Morishima C; Bryan AB; Fink SL; Cohen S; Mani NS; Chaudhary A; Gardner GC
Ann Rheum Dis; 2021 Oct; 80(10):e165. PubMed ID: 34340981
[No Abstract] [Full Text] [Related]
3. Response to: 'Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'' by Westhoff
Bonelli M; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):e163. PubMed ID: 34272251
[No Abstract] [Full Text] [Related]
4. Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response"by Bonelli
Benucci M; Damiani A; Infantino M; Manfredi M; Grossi V; Lari B; Li Gobbi F; Sarzi Puttini P
Ann Rheum Dis; 2021 Oct; 80(10):e166. PubMed ID: 34340979
[No Abstract] [Full Text] [Related]
5. Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli
Bonelli M; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):e167. PubMed ID: 34340982
[No Abstract] [Full Text] [Related]
6. Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy.
Teh BW; Tam CS
Leuk Lymphoma; 2021 Dec; 62(12):2820-2822. PubMed ID: 34313175
[No Abstract] [Full Text] [Related]
7. Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists.
Santosa A; Xu C; Arkachaisri T; Kong KO; Lateef A; Lee TH; Leong KH; Low AHL; Sriranganathan MK; Tan TC; Teng GG; Thong BY; Fong W; Lahiri M
Int J Rheum Dis; 2021 Jun; 24(6):746-757. PubMed ID: 33973379
[TBL] [Abstract][Full Text] [Related]
8. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient.
Hill JA; Ujjani CS; Greninger AL; Shadman M; Gopal AK
Cancer Cell; 2021 Aug; 39(8):1037-1038. PubMed ID: 34242571
[No Abstract] [Full Text] [Related]
10. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
[No Abstract] [Full Text] [Related]
11. Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Doevelaar A; Hölzer B; Paniskaki K; Dolff S; Wilde B; Witzke O; Braun J; Stervbo U; Babel N
Ann Rheum Dis; 2021 Oct; 80(10):e162. PubMed ID: 34272253
[No Abstract] [Full Text] [Related]
12. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
13. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
Spiera R; Jinich S; Jannat-Khah D
Ann Rheum Dis; 2021 Oct; 80(10):1357-1359. PubMed ID: 33975857
[No Abstract] [Full Text] [Related]
14. [COVID-19 vaccines: the facts].
Maas DPMSM; Wijnans EG; van der Zeijst BAM; Kramers C
Ned Tijdschr Geneeskd; 2021 Aug; 165():. PubMed ID: 34351716
[TBL] [Abstract][Full Text] [Related]
15. Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines.
Schulze-Koops H; Specker C; Skapenko A
RMD Open; 2021 Feb; 7(1):. PubMed ID: 33627439
[TBL] [Abstract][Full Text] [Related]
16. [Current state of vaccination against SARS-CoV-2].
Iking-Konert C; Specker C; Krüger K; Schulze-Koops H; Aries P
Z Rheumatol; 2021 Mar; 80(2):158-164. PubMed ID: 33528655
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 vaccination efficacy and B-cell depletion therapy in systemic lupus erythematosus: Description of a case.
Ceccarelli F; Olivieri G; Natalucci F; Alessandri C; Conti F
Lupus; 2021 Sep; 30(10):1698-1699. PubMed ID: 34192958
[No Abstract] [Full Text] [Related]
18. Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey.
Barrière J; Gal J; Hoch B; Cassuto O; Leysalle A; Chamorey E; Borchiellini D
Ann Oncol; 2021 May; 32(5):673-674. PubMed ID: 33529740
[No Abstract] [Full Text] [Related]
19. COVID-19 vaccination and antirheumatic therapy.
Arnold J; Winthrop K; Emery P
Rheumatology (Oxford); 2021 Aug; 60(8):3496-3502. PubMed ID: 33710296
[TBL] [Abstract][Full Text] [Related]
20. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V
Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
